ClinicalTrials.gg
Not yet recruitingNCT07803146CREADEVUpdated Sep 3, 2026

Creative Processes and Children With a Neurodeveloppement Disorder

An observational study in Neurodevelopmental Disorders (NDD), sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting at 1 site in France. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
212
Ages
6 Years to 12 Years
Sex
All
01

Study summary

Neurodevelopmental disorders (NDDs) are associated with diverse cognitive profiles, including creative abilities that remain poorly documented. Studying creative processes in children helps to deepen our understanding of cognitive and developmental functioning in NDDs and to explore the development of more appropriate and inclusive assessment and support tools

Read the detailed description

Once consent has been obtained, the assessments are carried out within the Child and Adolescent Psychiatry Department at Robert-Debré Hospital.

The verbal and figural tests will be administered by a neuropsychologist or a trained doctor, following a standardised procedure:

  • AUT (verbal)
  • Ocsai-D
  • LEGO building task
  • Paediatric ICAA parent questionnaire
02

Conditions studied

  • Neurodevelopmental Disorders (NDD)

Keywords

  • psychiatry
  • pediatry
  • creativity
03

In context

Neurodevelopmental Disorders

352 studies on the registry are indexed under Neurodevelopmental Disorders; 141 are open to participants now.

This study's planned enrollment of 212 is close to the median of 200 across 133 observational studies indexed under Neurodevelopmental Disorders.

Browse Neurodevelopmental Disorders studies →

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,592 studies on the registry; 1,033 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Children aged between 6 and 12 with a neurodevelopmental disorder, who are hospitalised in the ward.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children aged 6 to 12 years
  • Prior inclusion in one of the existing clinical cohorts
  • No objection from those with parental authority
  • Consent from the participant, who must have read and understood the information leaflet
  • No acute malnutrition or acute medical condition

Exclusion criteria

Exclusion Criteria:

  • Acute malnutrition or ongoing parenteral nutrition
  • Acute intercurrent medical condition
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
212 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Composite creative Score

    To characterise performance in creativity and divergent thinking among patients with TND, using a range of stimuli

    Time frame: 5 years

Secondary outcomes

  1. paediatric adaptation of the Inventory of Creative Activities and Achievement (ICAA).

    At day 1

    Time frame: A parent-completed questionnaire on children's creative achievements

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07803146
Collaborators
Paris Brain Institute (ICM)
Responsible party
Sponsor
First posted
Sep 3, 2026
Start date
Sep 15, 2026 (estimated)
Primary completion
Sep 15, 2031 (estimated)
Completion
Sep 15, 2031 (estimated)
Last update
Sep 3, 2026

Study contacts

Mylène FEFEU, MD
Contact
mylene.fefeu@aphp.fr
0140032002 ext. 0033
Mylène FEFEU, MD
principal investigator · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion